Skip to content

In-line Mechanical Insufflation-Exsufflation in the Management of Ventilated Patients

In-line Mechanical Insufflation-Exsufflation as an Alternative to Invasive Suction for Secretion Management in Ventilated Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05365620
Enrollment
120
Registered
2022-05-09
Start date
2015-07-01
Completion date
2018-07-01
Last updated
2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Clearance Impairment, Ventilation Therapy; Complications

Brief summary

Catheter suction (CS), the standard method for airway secretion management during mechanical ventilation, is invasive and has significant hemodynamic and traumatic side effects. In-line mechanical insufflation-exsufflation (IL-MIE) is a new, noninvasive technology that clears secretions by cough-simulation, without interrupting ongoing ventilation. It is not known whether IL-MIE can be safely and effectively used as an alternative to CS in ventilated patients. Methods: A randomized, controlled, non-inferiority study comparing a standard protocol of CS, with automatic IL-MIE (CoughSync, Ruxin Medical Systems, Beijing) performed every 30 minutes, with CS added only if needed, in post-operative ventilated patients.

Detailed description

The study was designed as a randomized, open-label, parallel, non-inferiority, controlled trial. The study was carried out in two Intensive Care Units - the Cardiac Surgery ICU at Anzhen Hospital, and the Critical Care Medicine ICU at Tian Tan Hospital - both in Beijing, China, over a 36 month period between July 2015 and July 2018. The study group included patients aged 18 to 75 years undergoing mechanical ventilation during the immediate recovery period following a cardiac or neuro-surgical procedure. Subjects were randomized to either a control group, managed for 8 hours with CS whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's, or a study group, managed for 8 hours with automatic IL-MIE treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with CS performed only if signs of airway secretion accumulation manifested despite ongoing IL-MIE. IL-MIE was performed using standard IL-MIE parameters (exsufflation pressure = -60 cm H2O, with flutter, 10 coughs/treatment). Before each CS treatment, 100% oxygen was administered for one minute, regardless of the patient's baseline oxygen requirement, as per standard operating protocol in that ICU. Before IL-MIE treatments, no additional oxygen was administered beyond the patient's baseline oxygen requirement. Pharmacological management in both groups included analgesia and sedation as routinely used postoperatively in those ICU's. Demographic information and vital signs were recorded for all subjects. Arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2 ) and oxygenation index (PaO2/FiO2) were defined as the primary end points of the study, and arterial partial pressure of carbon dioxide (PaCO2), pulseoximetry (SpO2), heart rate (HR), and ventilator parameters (inspired oxygen, tidal volume \[Vt\], peak inspiratory pressure \[PIP\], airway plateau pressure \[Pplat\], and PEEP) as secondary end points. All primary and secondary end-point data were recorded at baseline (2 minutes prior to starting the trial), and at 5 minutes, 4 hours and 8 hours after commencement of the trial. The number of CS treatments performed on each subject was recorded throughout the trial. Follow up for adverse events was performed during, and 48 hours after completion of, the trial. Statistical Analysis: The minimum sample size required to demonstrate non-inferiority, was calculated to be 49 in each cohort, or a total of 98 subjects in total. Collected data were analyzed with a mixed model with repeated measures (MMRM) considering all observations (2 minutes before commencement of the trial protocol, and at 5 minutes, 4 hours and 8 hours thereafter) and accounting for the baseline value of oxygenation. For the indices of oxygenation derived from blood gas measurements (PaO2, SaO2 , and oxygenation index), non-inferiority was evaluated by comparison to the two-sided 95% confidence interval of the treatment effect in the MMRM model, with non-inferiority between the IL-MIE and control cohorts established if the lower limit of the 95% confidence interval for the intergroup difference in least squares mean for a measured index was found to be higher than the pre-determined non-inferiority margin for that index. For comparison of other quantitative data between groups, a two-sample t-test or Wilcoxon rank sum test was used, based on the data distribution. For between-group comparison of subjects with significant adverse events, a chi-square test was used. The number of CS treatments performed in each cohort was analyzed post-hoc as an exploratory analysis.

Interventions

DEVICEMechanical In-Line Inexsufflation

In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.

PROCEDUREcatheter suction

catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.

Sponsors

Beijing Anzhen Hospital
CollaboratorOTHER
Alyn Pediatric & Adolescent Rehabilitation Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study was designed as a randomized, open-label, parallel, non-inferiority, controlled trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients undergoing mechanical ventilation during the immediate recovery period following a cardiac or neuro-surgical procedure * Ventilation expected to last more than 8 hours

Exclusion criteria

* acute spinal cord shock * recent airway trauma or surgery * cardiogenic pulmonary edema or ARDS necessitating ventilation with a peak end expiratory pressure (PEEP) equal to or greater than 6 cmH2O * pneumothorax * hemoptysis * severe ischemic heart disease * lung tumors * pulmonary Tuberculosis * history of lung transplantation * pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frameDescription
PaO2change from baseline to 5 minutesArterial partial pressure of oxygen
SaO2change from baseline to 5 minutesarterial oxygen saturation
PaO2/FiO2change from baseline to 5 minutesoxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen

Secondary

MeasureTime frameDescription
heart ratechange from baseline to 5 minutesheart rate
inspired oxygenchange from baseline to 5 minutespercent fraction inspired oxygen
ventilator peak airway plateau pressurechange from baseline to 5 minutesairway plateau pressure in CMH2O
ventilator peak inspiratory pressurechange from baseline to 5 minutespeak airway pressure in CMH2O
ventilator peak end expiratory pressurechange from baseline to 5 minutesairway end expiratory pressure in CMH2O
ventilator tidal volumechange from baseline to 5 minutestidal volume in ml
PaCO2change from baseline to 5 minutesarterial partial pressure of carbon dioxide
SpO2change from baseline to 5 minutesblood oxygen saturation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026